The Duke Division of Gynecologic Oncology is a leader in research, education and clinical care. Our internationally-recognized faculty provide expertise in the evaluation and treatment of cancers that affect the reproductive system. This includes advanced minimally invasive surgery, chemotherapy, palliative care and management of hereditary cancers.
We are also involved in a broad range of clinical and translational research and are committed to training the next generation of gynecologic oncology specialists. Our faculty have also served in prominent roles in the Society of Gynecologic Oncology (SGO) and other national and international organizations in the field.
The division faculty are involved in a broad range of research that includes translational laboratory work, clinical trials and health services. Some highlights include the work of Andrew Berchuck, MD as a leader of the Ovarian Cancer Association Consortium, which has identified a few dozen genetic variants that increase ovarian cancer risk.
Angles Secord, MD is principal investigator of national cooperative group and other clinical trials, and has an interest in the role of angiogenesis in ovarian cancer.
Brittany Davidson, MD has an interest in clinical trials, patient preferences in cancer care and novel therapeutic agents.
Laura Havrilesky, MD is involved in examining cost-effectiveness of various interventions in Gynecologic Oncology. This includes consideration of the relative value of care and patient preferences.
Paula Lee, MD is board certified in palliative care and is investigating the role early intervention by a palliative care specialist in patients with advanced ovarian cancer.
Leah McNally, MD specializes in gynecologic cancers, including uterine, ovarian, cervical, vaginal and vulvar cancers.
Haley Moss, MD, MBA specializes in gynecologic oncology, which includes the surgical management and chemotherapy of women with ovarian, uterine, cervical, vaginal and vulvar cancer, as well as patients with gestational trophoblastic disease. Her research interests include the evaluation of alternative payment models for cancer care, understanding the impact of state and federal level health policy on access to oncologic services, and cost-effectiveness analysis of novel cancer treatments.
Rebecca Previs, MD is working on translating what is learned at the laboratory bench into better therapies for patients. Research interests include early phase clinical trials, novel therapeutics, the microenvironment, and personalized medicine, and gaining a better understanding of the immune microenvironment to determine how cancer cells evade discovery by our own immune systems.
The gynecologic oncology fellowship program at Duke is designed to enable fellows to attain subspecialty certification. This training includes high volume clinical services as well as opportunities to train in both clinical and laboratory research to prepare for an academic career in gynecologic oncology.
Fellows are expected to mature into effective leaders and educators in the context of their interactions with the residents and students. They also become inculcated in the practice of accessing the medical literature in real time while caring for patients, as well as starting on a life-long commitment to learning that will carry forward in the decades after formal training is completed.
Duke’s gynecologic oncologists are specialists in treating women with cancers and preinvasive lesions that affect the reproductive system. This includes cancers of the ovary, fallopian tube, uterus, cervix, vagina and vulva as well as gestational trophoblastic disease. Our division provides care in all of the hospitals in the DUHS as well as at Wake Med Hospital in Raleigh and Alamance Regional Hospital in Burlington.
We employ the full spectrum of available treatment modalities including open, laparoscopic and robotic surgery, comprehensive surgical staging and sentinel lymph node mapping as well as cytoreductive procedures. We are also involved in management of chemotherapy (cytotoxics and biological agents), risk assessment and prevention of hereditary cancers and palliative care. We also participate in a broad range of therapeutic clinical trials that aim to improve the treatment of these cancers in the future.